MedPath

Pilot Study Repetitive Transcranial Magnetic Stimulation (rTMS) in Cannabis Craving

Phase 1
Withdrawn
Conditions
Cannabis Use
Interventions
Device: Repetitive Transcranial Magnetic Stimulation
Registration Number
NCT01031290
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Brief Summary

Background:

* Cannabis, also known as marijuana, is a commonly abused drug. There is no approved medication to treat cannabis addiction. The desire to use cannabis often increases when seeing others use it or seeing pictures of it. Researchers are interested in determining which parts of the brain are active when looking at pictures associated with cannabis.

* Repetitive transcranial magnetic stimulation (rTMS) uses magnetic pulses to stimulate the brain. These pulses can change activity in parts of the brain. Researchers are interested in determining whether rTMS can decrease activity in the parts of the brain that respond to cannabis, and thereby lessen cravings for cannabis.

Objectives:

- To determine whether transcranial magnetic stimulation can lower craving for cannabis when people who use cannabis are shown images that increase craving.

Eligibility:

- Individuals 18 years of age and older who are physically healthy and currently use cannabis (at least 3 times weekly for the past 2 years).

Design:

* The study will involve eight visits over 3 weeks, with each visit lasting 1 to 2 hours.

* Participants will have an initial assessment about cannabis use and provide blood and urine samples before beginning the study.

* Participants will have three magnetic resonance imaging (MRI) brain scans. The first MRI scan will look at the structure of the brain at rest. During the other two scans, participants will look at images related to and not related to cannabis use.

* The rTMS sessions (with either actual TMS or inactive \[sham\] TMS) will be held daily for 5 consecutive days. During these testing visits, researchers will ask questions related to drug use and craving, and collect urine and breath samples for further study.

* Participants will have two follow-up visits, 1 week and 2 weeks after the rTMS sessions, to evaluate memory and mood, and one final MRI brain scan at the end of the study.

Detailed Description

Primary objective:

Repetitive transcranial magnetic stimulation (rTMS) provides a non-invasive means of altering brain neural activity. This pilot study will test whether 5 days of rTMS reduces cue-induced cannabis craving and use in cannabis users.

Hypothesis:

We predict that active rTMS will significantly lower craving for cannabis compared with sham rTMS.

Study population:

Thirty healthy adult cannabis users (for at least 2 years, currently averaging 3 times weekly) with no other major psychiatric disorders except nicotine dependence (DSM IV criteria) will be recruited from the community.

Design:

Following a baseline phase to evaluate subject characteristics, subjects will be randomly assigned to receive 5 days of active or sham rTMS. rTMS at 1 Hz and strength 120% of the motor threshold will be applied to the dorsolateral prefrontal cortex (DLPFC) using a figure 8 coil , beginning 1 second after presentation of a cannabis-associated visual cue and lasting for 30 seconds. Brain site localization will use a computerized navigation system based on structural MRI scans obtained before the first session. Each rTMS session (lasting around 31 minutes) will consist of 54 trials (cue presentations): 36 with cannabis-associated cues and 9 each with non-drug-associated positive or neutral cues. No rTMS will be administered with the non-cannabis-associated cues. Subjects return for follow-up assessments one and two weeks after the final rTMS session.

Outcome measures:

The primary outcome measure will be cannabis craving assessed by the Marijuana Craving Questionnaire and visual analog scales before and after every rTMS session and at one- and two-week follow-up. Secondary outcome measures will be self-reported cannabis use and urine drug testing at each rTMS session and follow-up visit, and changes in regional brain responses to cannabis-associated visual cues assessed by fMRI done before and after the 5 rTMS sessions.

Benefits:

The future benefit to society may be development of better methods for treatment of cannabis addiction.

Risks:

The primary risks from rTMS are transient headache, scalp discomfort, decreased spatial recognition memory, and hearing loss (minimized by wearing ear plugs). Seizures are very rare when rTMS is administered within accepted safety guidelines and individuals at increased risk of seizures are excluded. The risk of inducing a manic episode is minimized by excluding individuals with a history of non-drug-induced mania/hypomania.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group BRepetitive Transcranial Magnetic StimulationSham TMS
Group ARepetitive Transcranial Magnetic StimulationActive TMS
Primary Outcome Measures
NameTimeMethod
Cannabis craving by Marijuana Craving Questionnaire and visual-analogue scales.2 weeks
Secondary Outcome Measures
NameTimeMethod
Cannabis use by urine drug testing and self-report; Safety and tolerability, using side-effects checklist.2 weeks

Trial Locations

Locations (1)

Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue

🇺🇸

Catonsville, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath